Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$339.54M+7.9%$314.7M-14.5%$368.29M+7.5%$342.45M+6.1%$322.75M+9.5%
$69.19M+9.3%$63.32M+14.2%$55.43M+13.6%$48.78M+9.4%$44.59M+13.5%
$408.74M+8.1%$378.02M-10.8%$423.72M+8.3%$391.23M+6.5%$367.35M+10.0%
-$183.47M-15.2%-$159.31M+23.7%-$208.88M+45.6%-$384.23M-6.6%-$360.35M-10.2%
$43.41M-4.8%$45.62M-5.3%$48.14M-8.2%$52.42M-1.6%$53.26M+1.5%
-$140.06M-23.2%-$113.7M+29.3%-$160.74M+51.6%-$331.8M-8.0%-$307.08M-11.9%
-$1.60-22.1%-$1.31+31.8%-$1.92+50.1%-$3.85-5.5%-$3.65-8.6%
-$180.68M-15.4%-$156.61M+24.1%-$206.33M+46.0%-$381.76M-6.6%-$357.98M-10.3%
-$183.47M-15.2%-$159.31M+23.7%-$208.88M+45.6%-$384.23M-6.6%-$360.35M-10.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is IDEAYA Biosciences, Inc.'s revenue?
IDEAYA Biosciences, Inc. (IDYA) generated $232.3M in revenue over the trailing twelve months, up 5822.2% year over year.
Is IDEAYA Biosciences, Inc. profitable?
IDEAYA Biosciences, Inc. is not currently profitable: it reported a net loss of $140.1M over the trailing twelve months, a -3921.1% net margin.
What is IDEAYA Biosciences, Inc.'s earnings per share?
IDEAYA Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-1.60.
Where does IDEAYA Biosciences, Inc.'s income statement data come from?
Every line is extracted from IDEAYA Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.